In the study of Koya et al. the combined treatment of pmel or OVA TCR gene-engineered ACT therapy plus vemurafenib has significantly improved antitumor activity by enhancing effector function of intratumoral T cells in SMA or SM1-OVA model, which provided strong theoretical support for the combinatorial regimen of targeted therapy and ACT therapy for the treatment of patient with metastatic melanoma harboring BRAF mutation (136). This evidence concerns the gene BRAF and metastatic melanoma.